Prevention of Human Papillomavirus and Vaccines Strategies
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Papillomavirus Vaccines".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 8426
Special Issue Editor
2. Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), Institute for Innovation, Capacity Building and Sustainability of Agri-Food Production (Inov4Agro), University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal
Interests: cancer cachexia; animal models of cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Human papillomavirus (HPV) causes the most common sexually transmissible infection worldwide and is associated with benign and malignant lesions of the ano-genital and head-and-neck regions. The development of HPV vaccines is a success story, leading to marked reductions in the incidence of cervical uterine lesions. However, multiple questions regarding HPV prevention remain unanswered, including which strategies might successfully implement vaccination across culturally heterogeneous communities, the extent of its efficacy in preventing specific lesions, how vaccines might be combined with other preventive strategies, and the potential therapeutic efficacy of HPV vaccines against established lesions. This Special Issue welcomes all kinds of contributions, including original research and review articles, on topics related to HPV prevention and vaccination. We expect this Special Issue to be an opportunity to advance scientific knowledge in this field and encourage more effective HPV approaches.
Prof. Dr. Rui Gil da Costa
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- human papillomavirus
- HPV vaccines
- vaccination strategies
- cervical cancer prevention
- therapeutic vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.